Posts in Uncategorized

Informed Consent Applications and Duplicate Marketing Authorisations: Using Article 10c for Co-Marketing in the EU

Not every new marketing authorisation needs a new dossier. Under Article 10c of Directive 2001/83/EC, a company can obtain its own authorisation for a medicine[…]

The EURD List and PSUSA: How Union Reference Dates Decide Your PSUR Obligations

For most marketing authorisation holders, the question of when a periodic safety update report is due is not answered by the marketing authorisation itself. It[…]

High-Cost Medicines Through Private Pharmacies in Greece: What the New EOPYY Model Means for Manufacturers

Since 5 February 2026, patients in Greece receiving certain high-cost medicines have been able to collect them from a private community pharmacy of their choice,[…]

US Most-Favoured-Nation Pricing and European Launches: What It Means for Market Access in Greece

Since the White House’s May 2025 executive order on most-favoured-nation (MFN) pricing, US drug prices have become increasingly linked to prices paid in other high-income[…]

Annex 11 and Annex 22 in Late 2026: What to Settle Now While the Final Texts Are Pending

More than a year after the consultation closed, the revised EU GMP Annex 11 on computerised systems and the new Annex 22 on artificial intelligence[…]

Continuous Compliance Monitoring for SaaS GxP Systems: Keeping Validation Current Through Every Vendor Release

Cloud and software-as-a-service platforms now run quality management, pharmacovigilance, regulatory information and laboratory processes across the industry. They also change on the vendor’s schedule, often[…]

FDA’s Final PDURS Guidance: When a Companion App Becomes Drug Labelling

In October 2026, the US Food and Drug Administration finalised its guidance on Prescription Drug Use-Related Software (PDURS), three years after the 2023 draft. It[…]

ICH M15 on Model-Informed Drug Development: How Regulators Will Judge Your Models

Modelling and simulation now support dose selection, paediatric extrapolation, drug interaction claims and trial design across most development programmes. ICH M15, adopted at Step 4[…]

ICH Q3E on Extractables and Leachables: Preparing for the First Harmonised E&L Guideline

Extractables and leachables have long been assessed through a patchwork of regional guidance, pharmacopoeial chapters and industry practice. ICH Q3E is set to become the[…]

ICH E6(R3) Annex 2: Good Clinical Practice for Decentralised, Pragmatic and Real-World Data Trials

ICH finalised Annex 2 to the E6(R3) Good Clinical Practice guideline on 3 June 2026. Where the core E6(R3) principles and Annex 1 describe GCP[…]

1 2 3 … 26